Objective To assess the efficacy of vilaprisan compared with placebo in the management of
the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive …

Objective Vilaprisan is a highly potent selective progesterone receptor modulator shown to
reduce heavy menstrual bleeding, induce amenorrhea, and diminish uterine fibroid volume …

Objectives To assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women
with uterine fibroids. Design Randomized, double-blind, placebo-controlled, multicenter trial …

Abstract Background Uterine fibroids (UFs) may be treated with progesterone receptor
modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the …

Objective Selective progesterone receptor modulators (SPRMs) in women with uterine
fibroids (UFs) reduce heavy menstrual bleeding (HMB) and tumor size. We report the results …

Aim To assess the efficacy and safety of long‐term intermittent administration of 10‐mg
ulipristal acetate (UPA) for symptomatic uterine fibroids in Japanese women. Methods Open …

Background: Vilaprisan (VPR) is a new orally available selective progesterone receptor
modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively …

Ulipristal acetate (UPA), is a selective progesterone-receptor modulator, it decreases fibroid
size and reduces menstrual bleeding. We reviewed its use at the Heart of England …

Objective To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg
daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design …

Ulipristal acetate (UA), a selective progesterone modulator, has been approved for short-
term therapy for symptomatic fibroids. We decided to undertake a systematic review of the …